Glaukos Corporation is an ophthalmic medical technology company dedicated to developing innovative products and procedures aimed at transforming the treatment of glaucoma, a major cause of blindness worldwide. The company has pioneered Micro-Invasive Glaucoma Surgery (MIGS) to enhance traditional glaucoma management approaches. Its flagship product, the iStent, was introduced in the United States in 2012 and is designed as a micro-bypass stent that can be inserted during cataract surgery to lower intraocular pressure in adults with mild-to-moderate open-angle glaucoma. Glaukos is also advancing its product pipeline with the iStent SA, a two-stent system that utilizes a unique auto-injection inserter for standalone procedures. Founded in 1998 and headquartered in San Clemente, California, Glaukos aims to build a comprehensive portfolio of injectable micro-scale therapies to address various glaucoma disease states and progression.
Avedro, Inc. is a medical device and pharmaceutical company specializing in the treatment of corneal disorders, particularly corneal ectatic conditions and refractive errors. The company has developed the Avedro Corneal Remodeling platform, which includes the KXL and Mosaic systems that utilize ultraviolet A (UVA) light, alongside a range of single-use riboflavin drug formulations. These technologies are primarily aimed at treating progressive keratoconus and corneal ectasia following refractive surgery. Avedro also focuses on advancing the science of Thermo-biomechanics, exemplified by its Keraflex procedure, a non-invasive method for corneal reshaping that preserves the cornea's biomechanical integrity. The company's products are marketed to ophthalmologists, hospitals, and ambulatory surgery centers in the United States and through international distributors. Avedro, originally established as ThermalVision, Inc. in 2002, is headquartered in Waltham, Massachusetts, and operates as a subsidiary of Glaukos Corporation.
DOSE Medical Corp.
Acquisition in 2019
DOSE Medical Corp. is developing multiple micro-invasive, bioerodible, sustained-release drug delivery platforms designed to be used in the treatment of various retinal diseases, including age-related macular degeneration (AMD) and diabetic macular edema.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.